NovaBay Pharmaceuticals Completes Enrollment in Phase 2 Impetigo Clinical Trial
NovaBay Pharmaceuticals Completes Enrollment in Phase 2 Impetigo Clinical Trial. New Class of Anti-infectives Addresses Rising Tide of Antibiotic Resistance. […]
		
					NovaBay Pharmaceuticals Completes Enrollment in Phase 2 Impetigo Clinical Trial. New Class of Anti-infectives Addresses Rising Tide of Antibiotic Resistance. […]
		
					Smith-Midland Corp
(OTC BB: SMID)
Interview with Rodney Smith, CEO and William Kenter, CFO […]
		
					EcoloCap Solutions Inc
(OTC BB: ECOS)
Interview with Michael Siegel, CEO […]
		
					Kona Grill
(NASDAQGM: KONA)
Interview with Marc Buehler, President and CEO […]
		
					Eastmain Resources
(TSX.V: ER)
Interview Donald Robinson, CEO and President […]
		
					Terrane Metals Corp
(TSX.V: TRX)
Interview with Robert Pease, CEO and President […]
		
					JBI, Inc. has completed a private placement with a total of 488,779 shares sold at $4.00 per share. […]
		
					Cogent Communications
(NASDAQ: CCOI)
Interview with David Schaeffer, CEO […]
		
					Aldrin Resource Corp
(TSX.V: ALN)
Interview with Johnathan More, CEO […]
		
					PuraMed BioScience
(OTC BB: PMBS)
Interview with Russell Mitchell, CEO […]
		
					Realm Energy
(TSX.V: RLM)
Interview with Craig Steinke, Executive Chairman […]
		
					ISE Limited
(TSX.V: ISE)
Interview with Rick Sander, CEO […]
		
					Cavan Ventures (TSX.V: CVN)
Interview with Ming Chiang, CEO and President, and Andrew Monar, Technical Advisor […]
		
					Vitro Diagnostics, Inc (OTC BB: VODG)
Interview with Dr. James Musick, CEO […]
		
					Avantair, Inc.
(OTC BB: AAIR)
Interview with Steve Santo, CEO […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.